Cargando…
Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability
Hepatocellular carcinoma (HCC) is one of the global health concerns. Hepatitis B virus (HBV) is one of the major causes of HCC. Poor clinical outcome of HCC patients is attributed to a small population of cancer cells known as cancer stem cells (CSCs). In this work, we studied the effect of inhibiti...
Autores principales: | Amin, Mohamed N., El-Far, Yousra M., El-Mowafy, Mohammed, Elgaml, Abdelaziz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634085/ https://www.ncbi.nlm.nih.gov/pubmed/37941056 http://dx.doi.org/10.1186/s13148-023-01593-8 |
Ejemplares similares
-
Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022) -
Data on the expression of PEPCK in HepG2 hepatocytes transfected with miR-195
por: Yang, Won-Mo, et al.
Publicado: (2017) -
The antimicrobial peptide alpha defensin correlates to type 2 diabetes via the advanced glycation end products pathway
por: El-Mowafy, Mohammed, et al.
Publicado: (2022) -
Data on the decreased expression of FOXO1 by miR-1271 in HepG2 hepatocytes
por: Yang, Won-Mo, et al.
Publicado: (2017) -
Viability of HepG2 and MCF-7 cells is not correlated with mitochondrial bioenergetics
por: Doczi, Judit, et al.
Publicado: (2023)